William F. Jester

William F. Jester

Auto-generated profile, based on publicly available information

William F. Jester

Institute for Translational Medicine and Science, Rutgers, The State University of New Jersey, New Brunswick, NJ, 08901 USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BHBlanca E. Himes
Blanca E. Himes
XJXiaofeng Jiang
Xiaofeng Jiang
PWPeter Wagner
Peter Wagner
RHRuoxi Hu
Ruoxi Hu
QWQiyu Wang
Qiyu Wang
QLQuan Lu
Quan Lu
Asthma is a chronic inflammatory respiratory disease that affects over 300 million people worldwide. Glucocorticoids are a mainstay therapy for asthma because they exert anti-inflammatory effects in multiple lung tissues, including the airway smooth muscle (ASM). However, the mechanism by which glucocorticoids suppress inflammation in ASM remains poorly understood. Using RNA-Seq, a high-throughput sequencing method, we characterized transcriptomic changes in four primary human ASM cell lines that were treated with dexamethasone—a potent synthetic glucocorticoid (1 µM for 18 hours). Based on a Benjamini-Hochberg corrected p-value <0.05, we identified 316 differentially expressed genes, including both well known (DUSP1, KLF15, PER1, TSC22D3) and less investigated (C7, CCDC69, CRISPLD2) glucocorticoid-responsive genes. CRISPLD2, which encodes a secreted protein previously implicated in lung development and endotoxin regulation, was found to have SNPs that were moderately associated with inhaled corticosteroid resistance and bronchodilator response among asthma patients in two previously conducted genome-wide association studies. Quantitative RT-PCR and Western blotting showed that dexamethasone treatment significantly increased CRISPLD2 mRNA and protein expression in ASM cells. CRISPLD2 expression was also induced by the inflammatory cytokine IL1β, and small interfering RNA-mediated knockdown of CRISPLD2 further increased IL1β-induced expression of IL6 and IL8. Our findings offer a comprehensive view of the effect of a glucocorticoid on the ASM transcriptome and identify CRISPLD2 as an asthma pharmacogenetics candidate gene that regulates anti-inflammatory effects of glucocorticoids in the ASM.

1 December 1998 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
LLLing-Hong Li
Ling-Hong Li
WJWilliam F. Jester
William F. Jester
JOJoanne M. Orth
Joanne M. Orth

1 August 2000 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
LLLing-Hong Li
Ling-Hong Li
WJWilliam F. Jester
William F. Jester
ALAndrew Laslett
Andrew Laslett
JOJoanne M. Orth
Joanne M. Orth

28 January 2019 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SDShiteng Duan
Shiteng Duan
CKCynthia Koziol-White
Cynthia Koziol-White
WJWilliam F. Jester Jr.
William F. Jester Jr.
CNCorwin M. Nycholat
Corwin M. Nycholat
MMMatthew Macauley
Matthew Macauley
JPJames C. Paulson
James C. Paulson
Allergen immunotherapy for patients with allergies begins with weekly escalating doses of allergen under medial supervision to monitor and treat IgE-mast cell mediated anaphylaxis. There is currently no treatment to safely desensitize mast cells to enable robust allergen immunotherapy with therapeutic levels of allergen. Here we demonstrated that liposomal nanoparticles bearing an allergen and a high-affinity glycan ligand of the inhibitory receptor CD33 profoundly suppressed IgE-mediated activation of mast cells, prevented anaphylaxis in transgenic mice with mast cells expressing human CD33, and desensitized mice from subsequent allergen challenge for several days. We showed that high levels of CD33 were consistently expressed on human skin mast cells, and that the antigenic-liposomes with CD33 ligand prevented IgE-mediated bronchoconstriction in slices of human lung. The results demonstrated the potential of exploiting CD33 to desensitize mast cells to provide a therapeutic window for administering allergen immunotherapy without triggering anaphylaxis.

12 February 2014 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
RHRuoxi Hu
Ruoxi Hu
WPWenchi Pan
Wenchi Pan
AFAlexey V. Fedulov
Alexey V. Fedulov
WJWilliam Jester
William Jester
MJMatthew R. Jones
Matthew R. Jones
QLQuan Lu
Quan Lu
Airway smooth muscle (ASM) cells play important physiological roles in the lung, and abnormal proliferation of ASM directly contributes to the airway remodeling during development of lung diseases such as asthma. MicroRNAs are small yet versatile gene tuners that regulate a variety of cellular processes, including cell growth and proliferation; however, little is known about the precise role of microRNAs in the proliferation of the ASM. Here we report that a specific microRNA (miR‐10a) controls ASM proliferation through directly inhibiting the phosphoinositide 3‐kinase (PI3K) pathway. Next‐generation sequencing identified miR‐10a as the most abundant microRNA expressed in primary human airway smooth muscle (HASM) cells, accounting for > 20% of all small RNA reads. Overexpression of miR‐10a reduced mitogen‐induced HASM proliferation by ~50%, whereas inhibition of miR‐10a increased HASM proliferation by ~40%. Microarray profiling of HASM cells expressing miR‐10a mimics identified 52 significantly down‐regulated genes as potential targets of miR‐10a, including the catalytic subunit α of PI3K ( PIK3CA ), the central component of the PI3K pathway. MiR‐10a directly suppresses PIK3CA expression by targeting the 3‘‐untranslated region (3‘‐UTR) of the gene. Inhibition of PIK3CA by miR‐10a reduced V‐akt murine thymoma viral oncogene homolog 1 (AKT) phosphorylation and blunted the expression of cyclins and cyclin‐dependent kinases that are required for HASM proliferation. Together, our study identifies a novel microRNA‐mediated regulatory mechanism for PI3K signaling and ASM proliferation and further suggests miR‐10a as a potential therapeutic target for lung diseases whose etiology resides in abnormal ASM proliferation.—Hu, R., Pan, W., Fedulov, A. V., Jester, W., Jones, M. R., Weiss, S. T., Panettieri, R. A., Jr., Tantisira, K., Lu, Q. MicroRNA‐10a controls airway smooth muscle cell proliferation via direct targeting of the PI3 kinase pathway. FASEB J . 28, 2347–2357 (2014). www.fasebj.org

1 September 1997 in Biology of Reproduction
Verified
Journal Article
Open access
PDF file
JOJoanne M. Orth
Joanne M. Orth
JQJianping Qiu
Jianping Qiu
WJWilliam F. Jester
William F. Jester
SPStephen Pilder
Stephen Pilder
Rat gonocytes migrate to the basement membrane during the first postnatal week, a change in position crucial for their survival. These cells express